title: The significance of galectin-3 as a new basal cell marker in prostate cancer.
abstract: Prostate cancer may originate from distinct cell types, resulting in the heterogeneity of this disease. Galectin-3 (Gal-3) and androgen receptor (AR) have been reported to play important roles in the progression of prostate cancer, and their heterogeneous expressions might be associated with different cancer subtypes. Our study found that in various prostate cancer cell lines Gal-3 expression was always opposite to AR expression and other luminal cell markers but consistent with basal cell markers including glutathione S-transferase-π and Bcl-2. This expression pattern was confirmed in human prostate cancer tissues. Our results also showed that prostate cancer cells positive with basal cell markers were more aggressive. Downregulation of Gal-3 expression resulted in increased apoptotic potential and decreased metastasis potential of prostate cancer cells. Our findings demonstrate for the first time that Gal-3 may serve as a new marker for basal characteristics of prostate cancer epithelium. This study helps us to better understand the heterogeneity of prostate cancer. The clinical significance of this study lies in the application of Gal-3 to distinguish prostate cancer subtypes and improve treatment efficacy with designed personalized therapy.
authors.affiliation: Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI 48201, USA. karmanos48201@gmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: V
authors.initials: V
authors.lastname: Balan
authors.forename: X
authors.initials: X
authors.lastname: Gao
authors.forename: P G
authors.initials: PG
authors.lastname: Reddy
authors.forename: D
authors.initials: D
authors.lastname: Kho
authors.forename: L
authors.initials: L
authors.lastname: Tait
authors.forename: A
authors.initials: A
authors.lastname: Raz
mesh_terms: D000818:Animals; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation; D037502:Galectin 3 / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D018295:Neoplasms, Basal Cell / Q000378:metabolism* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011944:Receptors, Androgen / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D037502:Galectin 3; D011944:Receptors, Androgen
references.citation: Nat Genet. 1995 Apr;9(4):401-6
references.pmid: 7795646
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):181-6
references.pmid: 17185413
references.citation: Cancer Res. 2005 Dec 1;65(23):10946-51
references.pmid: 16322242
references.citation: Anticancer Res. 2002 Nov-Dec;22(6A):3117-25
references.pmid: 12530054
references.citation: Mod Pathol. 2008 Sep;21(9):1156-67
references.pmid: 18567993
references.citation: Am J Pathol. 1993 Aug;143(2):390-400
references.pmid: 7688182
references.citation: Cell Tissue Res. 2011 Dec;346(3):427-37
references.pmid: 22120666
references.citation: J Urol. 1990 Jan;143(1):167-71
references.pmid: 1688457
references.citation: Cancer Res. 2009 Nov 15;69(22):8555-62
references.pmid: 19887604
references.citation: Int J Cancer. 2010 Dec 1;127(11):2530-41
references.pmid: 20162566
references.citation: Discov Med. 2012 Feb;13(69):135-42
references.pmid: 22369972
references.citation: N Engl J Med. 1995 May 25;332(21):1393-8
references.pmid: 7723794
references.citation: J Urol. 1997 Feb;157(2):673-6
references.pmid: 8996396
references.citation: Nature. 2009 Sep 24;461(7263):495-500
references.pmid: 19741607
references.citation: Prostate. 1997 Jun 15;32(1):35-42
references.pmid: 9207955
references.citation: Am J Pathol. 2009 Apr;174(4):1515-23
references.pmid: 19286570
references.citation: Prostate. 1998 Nov 1;37(3):149-60
references.pmid: 9792132
references.citation: Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2610-5
references.pmid: 20133806
references.citation: J Bioenerg Biomembr. 2007 Feb;39(1):79-84
references.pmid: 17318396
references.citation: PLoS One. 2010 Feb 25;5(2):e9427
references.pmid: 20195545
references.citation: Cell. 1995 Dec 15;83(6):835-9
references.pmid: 8521507
references.citation: Endocrinology. 1991 Dec;129(6):3187-99
references.pmid: 1954898
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Prostate. 2008 Jan 1;68(1):72-7
references.pmid: 18008332
references.citation: Prostate. 1999 Aug 1;40(3):192-9
references.pmid: 10398281
references.citation: Science. 2010 Jul 30;329(5991):568-71
references.pmid: 20671189
references.citation: Mol Cell Endocrinol. 2012 Sep 5;360(1-2):14-24
references.pmid: 21802490
references.citation: Horm Cancer. 2011 Feb;2(1):47-61
references.pmid: 21761340
references.citation: Mol Cell Probes. 1992 Feb;6(1):59-65
references.pmid: 1312223
references.citation: Endocr Rev. 1995 Jun;16(3):271-321
references.pmid: 7671849
references.citation: Steroids. 2012 Aug;77(10):996-1001
references.pmid: 22289337
references.citation: Annu Rev Physiol. 2011;73:401-12
references.pmid: 20936943
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5
references.pmid: 16432235
references.citation: Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9
references.pmid: 12231070
references.citation: Am J Pathol. 2000 Dec;157(6):1769-75
references.pmid: 11106548
references.citation: Exp Cell Res. 1998 Dec 15;245(2):294-302
references.pmid: 9851870
references.citation: Curr Opin Urol. 2012 Sep;22(5):415-20
references.pmid: 22825460
references.citation: J Natl Cancer Inst. 1995 Mar 1;87(5):348-53
references.pmid: 7853416
references.citation: Pathol Res Pract. 1995 Dec;191(12):1214-21
references.pmid: 8927569
references.citation: Clin Sci (Lond). 2005 Jan;108(1):1-11
references.pmid: 15384949
references.citation: Cancer Res. 2005 Jul 1;65(13):5730-9
references.pmid: 15994948
references.citation: J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):307-13
references.pmid: 10419007
references.citation: Prostate. 2000 Jul 1;44(2):118-23
references.pmid: 10881021
references.citation: Cancer Res. 1992 Sep 15;52(18):4942-7
references.pmid: 1325287
references.citation: Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10705-10
references.pmid: 9380699
references.citation: J Endocrinol Invest. 2011 Mar;34(3):232-43
references.pmid: 21297383
references.citation: World J Urol. 2013 Apr;31(2):351-8
references.pmid: 22892876
references.citation: Int J Oncol. 2001 Jul;19(1):59-64
references.pmid: 11408923
references.citation: Endocr Pathol. 2011 Mar;22(1):35-9
references.pmid: 21234707
references.citation: Urol Res. 1999 Oct;27(5):362-7
references.pmid: 10550525
references.citation: PLoS One. 2009 May 22;4(5):e5662
references.pmid: 19461893
references.citation: J Biol Chem. 1996 Aug 16;271(33):19900-7
references.pmid: 8702703